Price falls when supply increases. The same goes for the pharmaceutical market.

Although the government can reduce fiscal spending by inducing competition between pharmaceutical companies, this would lead to a delay in NHI reimbursement listing.

As we enter the era of high-priced drugs, the government has been exercising the ‘art of waiting.’ If new drugs of the same class apply for listing and the approval of its latecomer(s) is expected soon, it is not uncommon for the authorities to concurrently conduct reimbursement deliberations for the two, even three new drugs at once.

The combination therapy using 'faslodex’ for breast cancer that was approved in 2019 was one e